艾拉莫德联合常规治疗对不同IgG滴度类风湿关节炎患者疗效与安全性的回顾性分析

目的:探讨艾拉莫德对血清免疫球蛋白G(IgG)升高的类风湿关节炎(RA)患者的远期临床疗效及安全性。方法:采用回顾性分析方法,收集某院2018年1~12月在常规治疗疗效不明显基础上联合使用艾拉莫德的活动性RA患者的临床资料,根据患者IgG滴度分为IgG升高组和IgG未升高组,比较治疗24周后两组的疾病活动性评分(DAS28),以及C-反应蛋白(CRP)、红细胞沉降率(ESR)、类风湿因子(RF)、IgG水平变化和药品不良反应。结果:治疗前,两组患者的IgG水平差异有统计学意义(P<0.05)。治疗后,IgG升高组患者的CRP、ESR、RF、IgG较前显著下降(P<0.05),IgG未升高组的CRP、ESR较前显著下降(P<0.05);且IgG升高组的ESR、RF显著低于IgG未升高组(P<0.05)。两组DAS28评分治疗前后均无显著变化,组间也无明显差异(P>0.05)。两组药品不良反应发生率差异无统计学意义(P>0.05)。结论:在常规治疗方案基础上联用艾拉莫德对两组均显示出一定的效果,主要表现为各种检验指标的改善,而IgG升高组改善更为明显。

Retrospective Analysis of the Efficacy and Safety of Iguratimod Combined with Conventional Therapy in Patients with Rheumatoid Arthritis with Different IgG Titers

Objective:To investigate the long-term clinical efficacy and safety of iguratimod in patients with rheumatoid arthritis(RA)with IgG titer elevation.Methods:Clinical data were collected from active RA patients treated in our hospital who were treated with iguratimod on the basis of poor efficacy of conuentional therapy from January 2018 to December 2018 and retrospective analysed.The clinical data of patients were divided into IgG elevation group and IgG non-elevation group according to the IgG drop degree.The disease activity score(DAS28),c-reactive protein(CRP),erythrocyte sedimentation rate(ESR),rheumatoid factor(RF),IgG level changes and adverse drug reactions were compared t after the treatment of iguratimod after 24 weeks.Results:Before the treatment,there was a statistically significant difference in IgG titer between the two groups(P<0.05).After the treatment,the CRP,ESR,RF and IgG titer in IgG elevation group were significantly decreased than before(P<0.05),while the CRP and ESR in IgG non-elevation group were significantly decreased than before(P<0.05).The ESR and RF of IgG elevated group were significantly lower than those of non-IgG elevation group(P<0.05).There were no significant difference in DAS scores after the treatment in and between the two groups(P>0.05).The incidence of adverse drug reactions had no significant difference between the two groups(P>0.05).Conclusion:On the basis of conventional treatment regimen,the combination of iguratimod shows certain effects in both groups,mainly manifesting in the improvement of various test indicators,while the improvement is more obvious in the group with increased IgG.